Clinical trial · Interventional
Patient-reported Outcomes in Neuroendocrine Neoplasms: a Prospective Quality of Life and Quality of Care Study Within NETwerk
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neuroendocrine tumors (NET) are rare tumors that require specific diagnosis and treatment. Therefore, this poses a challenge for clinical practice. Diagnosis and treatment can be optimized when physician specialists and other healthcare providers, across various hospitals, join forces to provide patients the best care. Based on this idea, a hospital network called NETwerk was set up. The following hospitals are part of this network: University Hospital Antwerp, VITAZ, AZ Monica, AZ Voorkempen, AZ Klina, Gasthuiszusters Antwerpen, Ziekenhuis Netwerk Antwerpen and AZ Rivierenland. In this NETwerk, patients with a neuroendocrine tumor or patients suspected with a neuroendocrine tumor are discussed with the specialists and treated.The aim of this study is to map the quality of life of NET patients within NETwerk in order to optimize the quality of care. Throughout the diagnosis, the treatment process and the follow-up, the patient will be asked to fill out three questionnaires (QLQ-C30, QLQ-GI.NET21 and a satisfaction survey). These questionnaires will be filled out every six months at home. Patients will be asked to complete these questionnaires over a period of five years.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Quality of Life | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EORTC QLQ-C30 | Procedure | — | UNRESOLVED |
| EORTC QLQ-GI.NET21 | Procedure | — | UNRESOLVED |
| Satisfaction survey | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- NEN patients
- description
- EORTC QLQ-C30, EORTC QLQ-GI.NET21 and satisfaction survey
- interventionNames
- Procedure: EORTC QLQ-C30
- Procedure: EORTC QLQ-GI.NET21
- Procedure: Satisfaction survey
Primary outcomes (2)
- measure
- Quality of life measurement with QLQ-C30 questionnaire
- timeFrame
- 5 years
- description
- Quality of life measurement with QLQ-C30 questionnaire
- measure
- Quality of life measurement with QLQ-GI.NET21 questionnaire
- timeFrame
- 5 years
- description
- Quality of life measurement with QLQ-GI.NET21 questionnaire
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * NEN patient * 18 years or older * Patient should appear in Oncobase Exclusion Criteria: * Patients who do not have an email address
References
Publications (0)
Data not yet available